Gilead Corp (GILD) - מקדם חוב לטווח ארוך להון

The price trend for Gilead Sciences, Inc. (GILD) on GURU.Markets, where the metric stands at 1.89, correlates with the performance of the oncology and HIV segments. The business relies on global sales of chronic disease medications while expanding its portfolio beyond viral therapy. The company's success is based on patent purity, regulatory approval of new formulas, and the volume of government medical procurement.

This indicator measures the share of long-term liabilities within the equity structure, allowing for an assessment of the issuer's financial stability and the risk of over-leverage during market shocks. By analyzing the long-term debt-to-net assets ratio, an investor can see how Gilead Sciences, Inc. (GILD) finances its expansion into oncology and protects its dominant positions in HIV therapy while maintaining a balance between borrowed capital and high capitalization.